doi: 10.1016/j.clinbiochem.2008.11.008.
Epub 2008 Dec 3.
Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays
Affiliations
- PMID: 19094976
- DOI: 10.1016/j.clinbiochem.2008.11.008
Item in Clipboard
Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays
Clin Biochem.
2009 Mar.
Abstract
Objectives: To identify autoantibody signatures in ovarian cancer using protein microarray technology.
Design and methods: Protein microarrays were screened using non-malignant peritoneal fluid (n=30) and ascites fluid pooled from ovarian cancer patients (n=30).
Results: Fifteen potential tumour-associated antigens were discovered. AASDHPPT showed the strongest signal-to-noise ratio.
Conclusions: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.
Similar articles
-
Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients.J Immunol Methods. 2008 May 20;334(1-2):37-50. doi: 10.1016/j.jim.2008.01.022. Epub 2008 Feb 21. J Immunol Methods. 2008. PMID: 18314130
-
Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays.Cancer Biomark. 2010-2011;8(4-5):293-307. doi: 10.3233/CBM-2011-0215. Cancer Biomark. 2010. PMID: 22045360
-
The "reverse capture" autoantibody microarray : an innovative approach to profiling the autoantibody response to tissue-derived native antigens.Methods Mol Biol. 2008;441:175-92. doi: 10.1007/978-1-60327-047-2_12. Methods Mol Biol. 2008. PMID: 18370319
-
Identifying autoantibody signatures in cancer: a promising challenge.Expert Rev Proteomics. 2009 Aug;6(4):377-86. doi: 10.1586/epr.09.56. Expert Rev Proteomics. 2009. PMID: 19681673 Review.
-
A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth.Cancer Lett. 2009 Aug 18;281(1):8-23. doi: 10.1016/j.canlet.2008.11.009. Epub 2008 Dec 16. Cancer Lett. 2009. PMID: 19091462 Review.
Cited by
-
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.Oncoimmunology. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. eCollection 2019. Oncoimmunology. 2019. PMID: 31428516 Free PMC article.
-
Identification of key gene modules and genes in colorectal cancer by co-expression analysis weighted gene co-expression network analysis.Biosci Rep. 2020 Sep 30;40(9):BSR20202044. doi: 10.1042/BSR20202044. Biosci Rep. 2020. PMID: 32815531 Free PMC article.
-
Autoantibody signature for the serologic detection of ovarian cancer.J Proteome Res. 2015 Jan 2;14(1):578-86. doi: 10.1021/pr500908n. Epub 2014 Nov 17. J Proteome Res. 2015. PMID: 25365139 Free PMC article.
-
Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.Proteomes. 2021 May 25;9(2):25. doi: 10.3390/proteomes9020025. Proteomes. 2021. PMID: 34070600 Free PMC article. Review.
-
The role of biomarkers in the management of epithelial ovarian cancer.Expert Rev Mol Diagn. 2017 Jun;17(6):577-591. doi: 10.1080/14737159.2017.1326820. Epub 2017 May 15. Expert Rev Mol Diagn. 2017. PMID: 28468520 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
